A Randomised, Open-labelled, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of the Pre-filled Pen and PFS of SB5 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Samsung Bioepis
- 09 Jun 2016 According to a Biogen media release, data from this study was presented at the Annual European Congress of Rheumatology (EULAR 2016).
- 24 Nov 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 26 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.